Ritalin · Concerta · Medikinet · Focalin
Methylphenidate
stimulant · first-line in children
Effect (children)0.78 σ
Effect (adults)0.49 σ
Mechanismblocks DA/NE reuptake
Statuscontrolled
Documentary · ADHD treatments · June 2026
How much does it help?
Someone called it "a dark forest." Here it is mapped: every ADHD treatment on one axis, ranked by effect size from meta-analysis. Stimulants climb highest. Then what matters is what you can actually get — and there the US, UK, EU and Romania look nothing alike.
~1.0σ
amphetamine effect in children, the largest in the class*
4
non-stimulant molecules approved by the FDA
2
molecules on Romanian shelves: methylphenidate and atomoxetine
0
amphetamines actually stocked in Romanian pharmacies
Three families · stimulants, non-stimulants, supplements
What exists, in short
Two drug classes with solid evidence, plus a fringe of supplements without. Stimulants (methylphenidate and amphetamines) are first-line everywhere. Non-stimulants are real options when stimulants don't work. Supplements are a separate category, handled below with the colour drained out.
Adderall · Vyvanse · Elvanse · Dexedrine
Amphetamines
stimulant · strongest in adults
Effect (children)1.02 σ
Effect (adults)0.79 σ
Mechanismreleases + blocks DA/NE
Statuscontrolled
Strattera · Atofab · Qelbree
Atomoxetine · viloxazine
non-stimulant · NE reuptake inhibitors
Effect (children)0.56 σ
Edgeno abuse potential; helps anxiety
Onsetweeks to full effect
StatusRx, uncontrolled
Intuniv · Kapvay · Onyda XR
Guanfacine · clonidine
non-stimulant · alpha-2A agonists
Effect (children)~0.67 σ
Useful fortics, aggression, sleep
Agemostly children/teens
StatusRx, uncontrolled
The signature · the effect-size ladder
Every option on one axis
Each point is a treatment, placed by how far it moves symptoms versus placebo (SMD — the "effect size," in standard deviations). The figures come mostly from the Cortese 2018 meta-analysis, the field's benchmark. Toggle children versus adults; filter by class. Tap any point.
On each point: molecule, mechanism, evidence, access.
How to read "effect size"
0.2 is a small effect, 0.5 medium, 0.8 large. An SMD of 1.0 means the average patient on the drug does better than ~84% of those on placebo. But it's an average: some people don't respond to the first molecule and respond beautifully to the second. "Strongest on paper" is not "best for you."
How they work · dopamine and noradrenaline
Four ways to reach the same circuit
ADHD involves dopamine and noradrenaline signalling in the prefrontal cortex — the region that holds attention, planning, the brakes. Each class reaches that circuit by a different route.
01 · stimulant
Amphetamines
Force the release of dopamine and noradrenaline and block their reuptake. They press the pedal from two directions — hence the largest effect, and hence the abuse potential that makes them controlled.
02 · stimulant
Methylphenidate
Blocks reuptake, without major forced release. Slightly smaller effect, a somewhat gentler profile — which is why it's first-line in children in most guidelines.
03 · non-stimulant
Atomoxetine · viloxazine · guanfacine
Atomoxetine and viloxazine raise noradrenaline by blocking its reuptake; guanfacine and clonidine tune alpha-2A receptors. Smaller effect, but no controlled-substance regime and no "crash." Atomoxetine takes weeks to reach full effect.
04 · supplement
Precursors and minerals
Mucuna pruriens delivers L-DOPA, the dopamine precursor; iron and zinc are cofactors in making it. The logic seems to close the loop — but a plausible mechanism is not clinical proof, and here the proof is almost entirely missing.
The crux · what you can actually get
Same science, four different pharmacies
The evidence is global. Access is not. A molecule from the top of the ladder can be on the shelf in one country and simply non-existent in another. Below, the same families read through four jurisdictions. Availability shifts often and varies by region — check locally.
| Family | SUA / US | UK | UE / EU | Romania |
|---|---|---|---|---|
| Methylphenidate | wideConcerta, Ritalin, Focalin | yesConcerta XL, Medikinet | wideeverywhere | yesConcerta |
| Amphetamines (Adderall etc.) | wideAdderall, Dexedrine | partialdexamf.; no Adderall | variesmixed salts rare | nonot stocked |
| Lisdexamfetamine (Elvanse/Vyvanse) | yes+ generic since 2023 | yesadult first-line | manyElvanse / Tyvense | on paperauthorised, not in pharmacies |
| Atomoxetine | genericbrand gone 2023 | yesStrattera | wideeverywhere | yesStrattera, Atofab |
| Viloxazine (Qelbree) | yeskids 2021, adults 2022 | nonot licensed | nofor ADHD | no— |
| Guanfacine / clonidine | yesIntuniv, Kapvay, Onyda XR | guanf.Intuniv | variesguanfacine in many | scarceno real presence |
SUA · US · FDA / DEA
The widest shelf, the steepest cost
Every class, every formulation: tablets, capsules, patches (Daytrana, Xelstrym), liquid suspensions, prodrugs. Four approved non-stimulant molecules, plus multiple formulations. Stimulants are Schedule II — tight prescriptions, quantity limits, DEA oversight. Telehealth opened prescribing, with rules still moving.
First-linea stimulant chosen by preference and insurance
Barrierprice without insurance; recurring Adderall/Vyvanse shortages
UK · NICE NG87 / MHRA
Clear rules, erratic shelves
Stimulants are first-line (methylphenidate in children; lisdexamfetamine or methylphenidate in adults). Atomoxetine and guanfacine follow. Adderall isn't licensed. Since 2023, a persistent structural shortage; easing in 2026 without normalising. Assessment waiting lists are long; the "Right to Choose" route shortens them.
Cost£9.90 flat per item (free in Scotland, Wales, NI)
Barrierthe wait; supply gaps; cost of the private assessment route
UE · EU · EMA + national
Not one Europe, but twenty-seven
The EU doesn't work as one pharmacy shelf: some ADHD medicines are recognised at European level, but availability, exact indication, reimbursement and prescribing remain national. Methylphenidate is everywhere. Lisdexamfetamine (Elvanse/Tyvense) is in many states, guanfacine in several, atomoxetine almost everywhere. Adderall doesn't exist in the EU. Adult licensing has widened, unevenly.
BetterDE, NL, the Nordics: wide range, adults included
Thinnereast and south: fewer molecules, underdeveloped adult diagnosis
ROMANIA · ANM / CNAS
Two molecules, and an adult gap
In practice the shelf has two options: methylphenidate (Concerta) and atomoxetine (Strattera, Atofab). Bupropion (Elontril) is used off-label. Amphetamines are absent; lisdexamfetamine is authorised on paper for generics but doesn't reach pharmacies. Guanfacine has no real presence. In 2024–2025, supply gaps for Concerta and atomoxetine.
Coverage100% (C3) for children and for 18–26 students without income; working adults pay in full
Initiationby a psychiatrist, continued by the GP; the old protocol discouraged adult initiation, though Concerta's label was updated in 2024 for adults (up to 72 mg)
Barrieradult diagnosis rare and hard to get; narrow range; stigma
The money · cost per month
The same pill, from 0 to 500 dollars
Price depends less on the molecule and more on the system. Figures are approximate, for one month at usual doses, and change often.
£0–9,90UK · NHS. A £9.90 flat charge per item in England; free in Scotland, Wales and Northern Ireland. The annual prepayment certificate is £114.50 regardless of how many items.
~100–200 leiRO · covered or not. Free (C3) for children and students without income. For a paying adult, Concerta runs roughly 100–200 lei a month (~€20–40), depending on dose and pharmacy.
$17–130US · generic. With coupons (GoodRx) or insurance, generic amphetamine or methylphenidate drops toward a few tens of dollars. Generic lisdexamfetamine, since 2023, cut a lot of the cost.
$400–558US · brand, uninsured. Brand Vyvanse, or brand Concerta, with no coverage, is the expensive end. Same drug, different barcode, ten times the price.
The hidden cost
The price of the pill is often the small part. The assessment — months of NHS waiting, hundreds of pounds privately, years and a hard-to-find psychiatrist in Romania — is the real barrier for many adults. A cheap drug doesn't help if you can't reach a diagnosis.
The world without evidence · supplements
What people take when they can't reach a doctor
Here the colour drains out of the page, because so does the evidence. A few supplements have a small, real effect — mostly correcting a deficiency. The rest rest on a plausible mechanism and testimonials. Nothing here matches a stimulant, and nothing here is regulated like a medicine.
| Supplement | The logic | What the evidence shows | Grade |
|---|---|---|---|
| Iron (if ferritin is low) | Cofactor in making dopamine; ferritin is often low in children with ADHD. | Useful when there's a documented deficiency. Not a treatment for those with normal iron. | small, conditional |
| Zinc | Involved in neurotransmitter metabolism; levels often lower in children with ADHD. | Meta-analyses show a modest signal, mostly with deficiency. Not a substitute for medication. | small, conditional |
| Omega-3 (EPA/DHA) | Fatty acids for neuronal membranes and signalling. | A small, consistent effect (~0.2 σ) in meta-analyses. An add-on, not a core therapy. | small, real |
| Saffron (Crocus sativus) | Dopamine/serotonin effects in preliminary studies. | A few small RCTs found it comparable to methylphenidate — but small, short, low certainty. | promising, weak |
| Bacopa, ginkgo, L-theanine | "Nootropic" botanicals; ginkgo on circulation, L-theanine on calm/sleep. | Bacopa shows some signal; ginkgo is below methylphenidate; L-theanine helps sleep, not attention. Few trials. | weak |
| Mucuna pruriens | Contains L-DOPA, dopamine's direct precursor — hence the appeal. | Zero direct clinical trials in ADHD. Only mechanism and testimony. Synthetic L-DOPA failed in adult ADHD trials. | no evidence |
Why mucuna is the edge case. The logic is clean: ADHD involves dysregulated dopamine and norepinephrine signalling, mucuna delivers L-DOPA, so the temptation is to see it as useful. But every step that seems to close the loop hides a problem. L-DOPA content varies batch to batch — you dose blind. Uncontrolled L-DOPA can bring nausea, agitation, blood-pressure swings, and long-term safety questions no one has studied in people with ADHD. And when synthetic, measurable L-DOPA was tested in ADHD, it didn't work. A precursor isn't a treatment just because the diagram looks right.
The map's edges · what we still don't know
The questions the ladder leaves out
| Long-term effects? | The trials behind the ladder run ~12 weeks. Beyond a year, randomised evidence is thin. The benefit seems to persist, but the question stays open. |
| Who responds to what? | The ladder is an average. There's still no test that predicts in advance which molecule fits you. In practice you try them in turn — a titration, not a formula. |
| The access gap? | Why does an adult in Timișoara have two molecules and one in Munich has ten, for the same condition and the same evidence? That's not a medical question but one of policy and regulation. |
| What's in the pipeline? | Centanafadine (Otsuka), a triple reuptake inhibitor, is under FDA priority review, with a PDUFA target action date of 24 July 2026. If approved, it would be the first genuinely new non-stimulant mechanism in years. |
Sources · meta-analyses, agencies, guidelines
Where the numbers come from
Efficacy: meta-analyses
- Effect sizes (SMD), the field's benchmark: Cortese et al., Lancet Psychiatry 2018 (PMC); data at med-adhd.org.
- Adult ADHD, intervention comparison: Lancet Psychiatry 2025.
- Guanfacine ER, effect size in children: Eur Neuropsychopharmacol; adolescenți.
- Viloxazine (Qelbree), phase 3 trials: analiză post-hoc; J Clin Psychiatry 2026.
- Quality of life on medication: JAACAP 2024.
Access, guidelines, agencies
- UK · NICE guidance and the medication shortage: MHRA / NHS Patient Safety Alert; NELFT NHS.
- US · FDA approvals and new non-stimulants: FDA; Qelbree adulți; Onyda XR; centanafadină; GoodRx.
- EU · use and licensing: DARWIN EU; Paxneury / guanfacină; metilfenidat.
- Romania · coverage, protocols, label, stock: About ADHD România (C3, N0020F/N0021F); notificări ANMDMR; ANMDMR · lisdexamfetamină; Concerta prospect.
- Prices: SingleCare (US); Community Pharmacy England.
Supplements
- Iron and zinc in ADHD: systematic review.
- Diet and supplements: systematic review 2024; L-teanină, cafeină, ginkgo, bacopa.
- Phytotherapy (saffron included): meta-analysis.
Effect sizes are trial averages (SMD vs placebo, clinician-rated, ~12 weeks), across different populations and durations; the head-to-head comparison is indicative. Viloxazine and saffron come from trials outside the benchmark meta-analysis and are flagged as such. The mucuna pruriens figure is missing because no ADHD clinical trials exist. Availability and coverage change often and vary by region.